A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
A study for patients with newly diagnosed Acute Myeloid Leukemia (AML) using study drug ASP2215
Sponsor: Astellas Pharma Inc.
Enrolling: Male and Female Patients
IRB Number: AAAO0661
U.S. Govt. ID: NCT02236013
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if a medicine called ASP2215 is both safe and effective as atreatment for patients with Acute Myeloid Leukemia (AML). ASP2215 is an experimental drug that is being studied to treat AML. In this study, ASP2215 will be given in addition to a standard chemotherapy regimen that patients could be receiving even if they were not participating in this study. The standard chemotherapy regimen patients receive includes cytarabine and idarubicin, however, there are other possible chemotherapy regimens they could receive depending on what their doctors thinks is best for them.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Have your received previous therapy for AML? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162